Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q2 2018 · 10-Q
Revenue—
Net Income-$307.28K-$307.28KN/M vs Q2 2017 EPS Diluted$0.00$0.00N/M vs Q2 2017 Operating Cash Flowderived-$6,509N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Jun 30, 2018 · filed Aug 13, 2018 · 44 d after period end